COVID-19 vs non-COVID-19 Patients Without Hematological Malignancies Treated for Invasive Pulmonary Aspergillosis

academic.oup.com March 18, 2025

COVID-19-associated pulmonary aspergillosis (CAPA) patients have less comorbidities and higher fungal burden compared to Putative Invasive Pulmonary Aspergillosis (PIPA), but clinical outcomes are similar between groups.

Independent predictor for better clinical cure was isavuconazole and for 30-day mortality was positive serum-GM.

Retrospective, monocentric comparative observational cohort study, including non-hematological patients treated for invasive pulmonary aspergillosis (IPA) between 2018-2022.

Primary study end points were risk factors for 30-day mortality and clinical failure.

To account for the imbalance in antifungal treatment allocation, propensity score (PS) weighting approach was adopted.